| 1. |
- Bybrant, Mara Cerqueiro, et al.
(författare)
-
The prevalence of having coeliac disease in children with type 1 diabetes was not significantly higher during the Swedish coeliac epidemic
- 2023
-
Ingår i: Acta Paediatrica. - : John Wiley & Sons. - 0803-5253 .- 1651-2227. ; 112:10, s. 2175-2181
-
Tidskriftsartikel (refereegranskat)abstract
- Aim: From 1986 to 1996, there was a four-fold increase in coeliac disease among young Swedish children, known as the Swedish coeliac epidemic. Children with type 1 diabetes have an increased risk of developing coeliac disease. We studied whether the prevalence of coeliac disease differed in children with type 1 diabetes born during and after this epidemic.Methods: We compared national birth cohorts of 240 844 children born in 1992–1993 during the coeliac disease epidemic and 179 530 children born in 1997–1998 after the epidemic. Children diagnosed with both type 1 diabetes and coeliac disease were identified by merging information from five national registers.Results: There was no statistically significant difference in the prevalence of coeliac disease among children with type 1 diabetes between the two cohorts: 176/1642 (10.7%, 95% confidence interval 9.2%–12.2%) in the cohort born during the coeliac disease epidemic versus 161/1380 (11.7%, 95% confidence interval 10.0%–13.5%) in the post-epidemic cohort.Conclusion: The prevalence of having both coeliac disease and type 1 diabetes was not significantly higher in children born during, than after, the Swedish coeliac epidemic. This may support a stronger genetic disposition in children who develop both conditions.
|
|
| 2. |
- FitzGerald, Edward A., et al.
(författare)
-
Multiplexed experimental strategies for fragment library screening using SPR biosensors
- 2020
-
Annan publikation (övrigt vetenskapligt/konstnärligt)abstract
- Surface plasmon resonance biosensor technology (SPR) is ideally suited for fragment-based lead discovery. However, generally suitable experimental procedures or detailed protocols are lacking, especially for structurally or physico-chemically challenging targets or when tool compounds are lacking. Success depends on accounting for the features of both the target and the chemical library, purposely designing screening experiments for identification and validation of hits with desired specificity and mode-of-action, and availability of orthogonal methods capable of confirming fragment hits. By adopting a multiplexed strategy, the range of targets and libraries amenable to an SPR biosensor-based approach for identifying hits is considerably expanded. We here illustrate innovative strategies using five challenging targets and variants thereof. Two libraries of 90 and 1056 fragments were screened using two different flow-based SPR biosensor systems, allowing different experimental approaches. Practical considerations and procedures accounting for the characteristics of the proteins and libraries, and that increase robustness, sensitivity, throughput and versatility are highlighted.Competing Interest StatementAnna Moberg, Maria T. Lindgren and Claes Holmgren work for Cytiva, which produce Biacore systems.
|
|
| 3. |
- FitzGerald, Edward, et al.
(författare)
-
Multiplexed experimental strategies for fragment library screening against challenging drug targets using SPR biosensors
- 2024
-
Ingår i: SLAS Discovery. - : Elsevier. - 2472-5552 .- 2472-5560. ; :1, s. 40-51
-
Tidskriftsartikel (refereegranskat)abstract
- Surface plasmon resonance (SPR) biosensor methods are ideally suited for fragment-based lead discovery. However, generally applicable experimental procedures and detailed protocols are lacking, especially for structurally or physico-chemically challenging targets or when tool compounds are not available. Success depends on accounting for the features of both the target and the chemical library, purposely designing screening experiments for identification and validation of hits with desired specificity and mode-of-action, and availability of orthogonal methods capable of confirming fragment hits. The range of targets and libraries amenable to an SPR biosensor-based approach for identifying hits is considerably expanded by adopting multiplexed strategies, using multiple complementary surfaces or experimental conditions. Here we illustrate principles and multiplexed approaches for using flow-based SPR biosensor systems for screening fragment libraries of different sizes (90 and 1056 compounds) against a selection of challenging targets. It shows strategies for the identification of fragments interacting with 1) large and structurally dynamic targets, represented by acetyl choline binding protein (AChBP), a Cys-loop receptor ligand gated ion channel homologue, 2) targets in multi protein complexes, represented by lysine demethylase 1 and a corepressor (LSD1/CoREST), 3) structurally variable or unstable targets, represented by farnesyl pyrophosphate synthase (FPPS), 4) targets containing intrinsically disordered regions, represented by protein tyrosine phosphatase 1B (PTP1B), and 5) aggregation-prone proteins, represented by an engineered form of human tau (tau K18M). Practical considerations and procedures accounting for the characteristics of the proteins and libraries, and that increase robustness, sensitivity, throughput and versatility are highlighted. The study shows that the challenges for addressing these types of targets is not identification of potentially useful fragments per se, but establishing methods for their validation and evolution into leads.
|
|
| 4. |
- Lindgren, Moa, et al.
(författare)
-
Type IV collagen as a potential biomarker of metastatic breast cancer
- 2021
-
Ingår i: Clinical and Experimental Metastasis. - : Springer. - 0262-0898 .- 1573-7276. ; 38:2, s. 175-185
-
Tidskriftsartikel (refereegranskat)abstract
- No reliable, non-invasive biomarker of metastatic breast cancer (mBC) exists: circulating CA15-3 (cCA15-3) is the marker mostly used to monitor mBC. Circulating collagen IV (cCOLIV) has been evaluated in other metastatic cancers and has been found to be a promising biomarker. The overarching aim of this study was to evaluate cCOLIV as a potential biomarker in patients with mBC. The first aim was to determine the levels of cCOL IV and cCA15-3 in patients with healthy controls, primary breast cancer (pBC) and mBC. The second aim was to compare levels of cCOLIV and cCA15-3 in patients with different metastatic sites of BC. The third aim was to investigate the prognostic value of cCOLIV and cCA15-3 for mBC patients. The fourth aim was to analyse whether a combination of the two biomarkers was more accurate in detecting mBC than a single marker. Lastly, we investigated the tissue expression levels of COLIV in BC bone metastases (BM) and liver metastases (LM). Plasma levels of cCOLIV and cCA15-3 from healthy controls and patients with pBC and mBC were measured. COLIV expression in tissue from patients with LM and BM was analysed using immunohistochemistry. Clinical and survival data were collected from medical charts. The levels of cCOLIV and cCA15-3 were significantly elevated in mBC patients compared with healthy controls and pBC patients. No differences in cCOLIV and cCA15-3 levels were found based on the metastatic site. High levels of cCOLIV, but not cCA15-3, correlated with poorer survival. cCOLIV alone and the combination of cCA15-3 and cCOLIV were superior to cCA15-3 at detecting mBC. COL IV was highly expressed in the tissue of LM and BM. Our study suggests that cCOLIV is a potential marker to monitor patients with BC.
|
|
| 5. |
- Lindgren, Moa, 1990-
(författare)
-
Type IV collagen in breast and colorectal cancer : a potential biomarker of metastatic disease
- 2022
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Background: Metastatic colorectal cancer (mCRC) and metastatic breast cancer (mBC) are two leading causes of cancer-related mortality worldwide. Early detection of metastatic disease is critical, and sensitive, easily accessed and cost-effective biomarkers that can diagnose mBC and mCRC at an early stage would have high clinical value. The best circulating markers: CEA and CA 15-3 are suboptimal, but a combination with other proteins can improve their potential to detect metastatic disease. One potential source of new biomarkers is the tumor stroma, including the extracellular matrix (ECM), vasculature, and stromal cells like immune cells and fibroblasts. Both the tumor cell and stromal compartment are vital for cancer progression. A combination of biomarkers from both compartments could likely best reflect the heterogeneous nature of the metastatic disease. Stromal type IV collagen (COL IV) is the main constituent of the basement membrane of healthy tissues. COL IV is upregulated with some cancers, including colorectal liver metastases (CLM), and is considered a potential biomarker for CLM. The origin of elevated levels of COL IV in CLM is not known but may result from both increased ECM production and ECM degradation associated with cancer-related tumor stroma remodeling. Aims: In this thesis, COL IV and its potential to be used as a biomarker for mCRC and mBC is studied, with a specific emphasis on liver metastases. The aims are to compare levels of circulating COL IV (cCOL IV) in mCRC and mBC patients with controls and evaluate its diagnostic and prognostic value; to evaluate the combination of cCOL IV with other proteins; to determine the cellular origin of COL IV in CLM and study COL IV expression in cell lines; to study the expression of COL IV degrading proteases in CLM and to evaluate tissue expression of COL IV in bone and liver metastases from BC patients. Methods: Plasma levels of cCOL IV, CA 15-3, CEA, and other cancer-related proteins were analyzed with ELISA, ECLIA and Multiplex assay in mCRC and mBC patients, healthy controls and patients with primary CRC or BC as controls. The cellular origin of COL IV expression in CLM was examined with in situ hybridization, and the expression of COL IV in mBC tissue and COL IV degrading proteases (MMP -2, -7, -9 and -13) in CLMs were studied with immunohistochemistry. COL IV expression in CRC and fibroblast cell lines was analyzed with immunofluorescence.Results: cCOL IV is elevated in mBC patients and correlates with poor survival. The combination of cCOL IV with CA 15-3 and cCOL IV alone are superior to CA 15-3 at detecting mBC. COL IV is highly expressed in the tissue of liver- and bone BC metastases. Circulating COL IV, CEA, OPN, CYFRA 21-1, IL-8, HGF, and MIF are elevated, and TRAIL is lower in mCRC patients compared with controls. COL IV, CEA, OPN, CYFRA 21-1, and IL-8 were higher, and TRAIL was lower in mCRC patients with liver metastases compared to patients with extrahepatic disease. Circulating CEA, OPN, and HGF are very good, and cCOL IV is acceptable at distinguishing mCRC patients from patients with primary CRC. The combination of OPN + CEA is superior to CEA alone at detecting mCRC. High HGF and cCOL IV (one cohort) in mCRC patients correlate to poor prognosis. cCOL IV is elevated in CLM patients compared to healthy controls and is very good at discriminating between healthy controls and CLM patients. COL IV is expressed in CLM by cancer-associated fibroblasts, and COL IV degrading proteases are expressed primarily by stromal cells in CLM. COL IV is expressed by fibroblasts, not tumor cells, in vitro. Conclusion: cCOL IV is a promising tumor marker of metastatic BC and CRC and circulating HGF and OPN are potential biomarkers of mCRC. Our results show that the metastatic site can impact the circulating levels of numerous cancer-related proteins, which aligns with our hypothesis that combining biomarkers instead of using one might be best for detecting metastatic cancer through blood analysis. COL IV is expressed by stromal cells, not tumor cells, in CLM tissue and in vitro.
|
|
| 6. |
- Lindgren, Moa, et al.
(författare)
-
Type IV Collagen in Human Colorectal Liver Metastases—Cellular Origin and a Circulating Biomarker
- 2022
-
Ingår i: Cancers. - : MDPI. - 2072-6694. ; 14:14
-
Tidskriftsartikel (refereegranskat)abstract
- Circulating type IV collagen (cCOL IV) is a potential biomarker for patients with colorectal liver metastases (CLM) who present with elevated levels of COL IV in both CLM tissue and circulation. This study aimed to establish the cellular origin of elevated levels of COL IV and analyze circulating COL IV in CLM patients. The cellular source was established through in situ hybridization, immunohistochemical staining, and morphological evaluation. Cellular expression in vitro was assessed by immunofluorescence. Tissue expression of COL IV-degrading matrix metalloproteinases (MMPs)-2, -7, -9, and -13 was studied with immunohistochemical staining. Plasma levels of COL IV in CLM patients and healthy controls were analyzed with ELISA. This study shows that cancer-associated fibroblasts (CAFs) express COL IV in the stroma of CLM and that COL IV is expressed in vitro by fibroblasts but not by tumor cells. MMP-2, -7, -9, and -13 are expressed in CLM tissue, mainly by hepatocytes and immune cells, and circulating COL IV is significantly elevated in CLM patients compared with healthy controls. Our study shows that stromal cells, not tumor cells, produce COL IV in CLM, and that circulating COL IV is elevated in patients with CLM.
|
|
| 7. |
- Lindgren, Paula, et al.
(författare)
-
Signatures of the post-hydration heating of highly aqueously altered CM carbonaceous chondrites and implications for interpreting asteroid sample returns
- 2020
-
Ingår i: Geochimica et Cosmochimica Acta. - : Elsevier BV. - 0016-7037. ; 289, s. 69-92
-
Tidskriftsartikel (refereegranskat)abstract
- The CM carbonaceous chondrites have all been aqueously altered, and some of them were subsequently heated in a parent body environment. Here we have sought to understand the impact of short duration heating on a highly aqueously altered CM through laboratory experiments on Allan Hills (ALH) 83100. Unheated ALH 83100 contains 83 volume per cent serpentine within the fine-grained matrix and altered chondrules. The matrix also hosts grains of calcite and dolomite, which are often intergrown with tochilinite, Fe(Ni) sulphides (pyrrhotite, pentlandite), magnetite and organic matter. Some of the magnetite formed by replacement of Fe(Ni) sulphides that were accreted from the nebula. Laboratory heating to 400 °C has caused partial dehydroxylation of serpentine and loss of isotopically light oxygen leading to an increase in bulk δ18O and fall in Δ17O. Tochilinite has decomposed to magnetite, whereas carbonates have remained unaltered. With regards to infrared spectroscopy (4000–400 cm−1; 2.5–25 µm), heating to 400 °C has resulted in decreased emissivity (increased reflectance), a sharper and more symmetric OH band at 3684 cm−1 (2.71 µm), a broadening of the Si[sbnd]O stretching band together with movement of its minimum to longer wavenumbers, and a decreasing depth of the Mg[sbnd]OH band (625 cm−1; 16 µm). The Si[sbnd]O bending band is unmodified by mild heating. With heating to 800 °C the serpentine has fully dehydroxylated and recrystallized to ∼Fo60/70 olivine. Bulk δ18O has further increased and Δ17O decreased. Troilite and pyrrhotite have formed, and recrystallization of pentlandite has produced Fe,Ni metal. Calcite and dolomite were calcined at ∼700 °C and in their place is an un-named Ca-Fe oxysulphide. Heating changes the structural order of organic matter so that Raman spectroscopy of carbon in the 800 °C sample shows an increased (D1 + D4) proportional area parameter. The infrared spectrum of the 800 °C sample confirms the abundance of Fe-bearing olivine and is very similar to the spectrum of naturally heated stage IV CM Pecora Escarpment 02010. The temperature-related mineralogical, chemical, isotopic and spectroscopic signatures defined in ALH 83100 will help to track the post-hydration thermal histories of carbonaceous chondrite meteorites, and samples returned from the primitive asteroids Ryugu and Bennu.
|
|
| 8. |
- Reithuber, Elisabeth, et al.
(författare)
-
THCz : Small molecules with antimicrobial activity that block cell wall lipid intermediates
- 2021
-
Ingår i: Proceedings of the National Academy of Sciences of the United States of America. - : National Academy of Sciences of the United States of America. - 0027-8424 .- 1091-6490. ; 118:47
-
Tidskriftsartikel (refereegranskat)abstract
- Emerging antibiotic resistance demands identification of novel antibacterial compound classes. A bacterial whole-cell screen based on pneumococcal autolysin-mediated lysis induction was developed to identify potential bacterial cell wall synthesis inhibitors. A hit class comprising a 1-amino substituted tetrahydrocarbazole (THCz) scaffold, containing two essential amine groups, displayed bactericidal activity against a broad range of gram-positive and selected gram-negative pathogens in the low micromolar range. Mode of action studies revealed that THCz inhibit cell envelope synthesis by targeting undecaprenyl pyrophosphate-containing lipid intermediates and thus simultaneously inhibit peptidoglycan, teichoic acid, and polysaccharide capsule biosynthesis. Resistance did not readily develop in vitro, and the ease of synthesizing and modifying these small molecules, as compared to natural lipid II-binding antibiotics, makes THCz promising scaffolds for development of cell wall-targeting antimicrobials.
|
|
| 9. |
- Wardlaw, Joanna M., et al.
(författare)
-
ESO Guideline on covert cerebral small vessel disease
- 2021
-
Ingår i: European Stroke Journal. - : SAGE Publications. - 2396-9873 .- 2396-9881. ; 6:2
-
Tidskriftsartikel (refereegranskat)abstract
- ‘Covert’ cerebral small vessel disease (ccSVD) is common on neuroimaging in persons without overt neurological manifestations, and increases the risk of future stroke, cognitive impairment, dependency, and death. These European Stroke Organisation (ESO) guidelines provide evidence-based recommendations to assist with clinical decisions about management of ccSVD, specifically white matter hyperintensities and lacunes, to prevent adverse clinical outcomes. The guidelines were developed according to ESO standard operating procedures and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. We prioritised the clinical outcomes of stroke, cognitive decline or dementia, dependency, death, mobility and mood disorders, and interventions of blood pressure lowering, antiplatelet drugs, lipid lowering, lifestyle modifications, glucose lowering and conventional treatments for dementia. We systematically reviewed the literature, assessed the evidence, formulated evidence-based recommendations where feasible, and expert consensus statements. We found little direct evidence, mostly of low quality. We recommend patients with ccSVD and hypertension to have their blood pressure well controlled; lower blood pressure targets may reduce ccSVD progression. We do not recommend antiplatelet drugs such as aspirin in ccSVD. We found little evidence on lipid lowering in ccSVD. Smoking cessation is a health priority. We recommend regular exercise which may benefit cognition, and a healthy diet, good sleep habits, avoiding obesity and stress for general health reasons. In ccSVD, we found no evidence for glucose control in the absence of diabetes or for conventional Alzheimer dementia treatments. Randomised controlled trials with clinical endpoints are a priority for ccSVD.
|
|
